Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 141, Issue 8, 2006, Pages 939-943

  Mata, Ignacio ^a   Crespo Facorro, Benedicto ^a   Pérez Iglesias, Rocío ^a   Carrasco Marín, Eugenio ^a   Arranz, Maria Jesús ^b   Pelayo Terán, José Maria ^a   Leyva Cobían, Francisco ^a   Vázquez Barquero, José Luis ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Cytokines; First episode; Schizophrenia; Treatment response

Indexed keywords

CYTOKINE; HALOPERIDOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BLOOD BANK; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; IL 1RN GENE; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH RESEARCH; NEGATIVE SYNDROME; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOM; SCHIZOPHRENIA; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; VARIANCE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HALOPERIDOL; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; POLYMORPHISM, GENETIC; RISPERIDONE; SCHIZOPHRENIA; SPAIN; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 33845415754     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30405     Document Type: Article

References (40)

1. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. 2004. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67:53-62.
2. Andreasen NC. 1984a. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa Press.
3. Andreasen NC. 1984b. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa Press.
4. Barak V, Barak Y, Levine J, Nisman B, Roisman I. 1995. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6:61-69.
5. Chowdari KV, Xu K, Zhang F, Ma C, Li T, Xie BY, Wood J, Trucco M, Tsoi WF, Saha N, Rudert WA, Nimgaonkar VL. 2001. Immune related genetic polymorphisms and schizophrenia among the Chinese. Hum Immunol 62:714-724.
6. Crespo-Facorro B, Pérez-Iglesias R, Ramírez ML, Martínez O, Llorca J, Vázquez-Barquero JL. 2006. A practical clinical trial comparing haloperidol, risperidone and olanzapine for the acute treatment of first episode of non-affective psychosis. J Clin Psychiatry (in press).
7. Danis VA, Millington M, Hyland VJ, Grennan D. 1995. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist gene polymorphism. Clin Exp Immunol 99:303-310.
8. Dunn AJ, Wang J. 1995. Cytokine effects on CNS biogenic amines. Neuroimmunomodulation 2:319-328.
9. Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U. 1987. Clinical and laboratory evidence of autoimmunity in schizophrenia. Ann NY Acad Sci 496:676-685.
10. Glatt SJ, Faraone SV, Tsuang MT. 2003. Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol Psychiatry 8:911-915.
11. Hanson DR, Gottesman II. 2005. Theories of schizophrenia: A genetic-inflammatory-vascular synthesis. BMC Med Genet 6:7.
12. Hurme M, Santilla S. 1998. IL-1 receptor antagonist plasma levels are coordinately regulated by both IL-1Ra and IL-1 genes. Eur J Immunol 28:2598-2602.
13. Katila H, Hanninen K, Hurme M. 1999. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 4:179-181.
14. Kim SJ, Lee HJ, Koo HG, Kim JW, Song JY, Kim MK, Shin DH, Jin SY, Hong MS, Park HJ, Yoon SH, Park HK, Chung JH. 2004. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr Genet 14:165-167.
15. Kronfol Z, Remick DJ. 2000. Cytokines and the brain: Implications for clinical psychiatry. Am J Psychiatry 157:683-694.
16. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HMD, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lönnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin J-L, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoëga T. Helgason T. 2003. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 73:34-48.
17. Leykin I, Mayer R, Shinitzky M. 1997. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37:75-86.
18. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M. 1998. The inflammatory response system in treatment resistant schizophrenia: Increased serum interleukin-6. Schizophr Res 32:9-15.
19. Malhotra AK, Murphy GM, Kennedy JL. 2004. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796.
20. Moots RJ, Al-Saffar Z, Hutchinson D, Golding SP, Young SP, Bacon PA, McLaughlin PJ. 1999. Old drugs, new tricks: Haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 59:585-587.
21. Muller N, Ackenheil M. 1998. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22:1-33.
22. Muller N, Riedel M, Ackenheil M, Schwarz MJ. 1999. The role of immune function in schizophrenia: An overview. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):62-68.
23. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ. 2002. Beneficial antipsychotics effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159:1029-1034.
24. Nawa H, Takahashi M, Patterson PH. 2000. Cytokine and growth factor involvement in schizophrenia-support for the developmental model. Mol Psychiatry 5:594-603.
25. Nicklin MJ, Weith A, Duff GW. 1994. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 19:382-384.
26. O'Callaghan E, Sham P, Takei N, Glover G, Murray RM. 1991. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet 337:1248-1250.
27. O'Callaghan E, Gibson T, Colohan HA, Buckley P, Walshe DG, Larkin C, Waddington JL. 1992. Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: A controlled study. Br Med J 305:1256-1259.
28. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
29. Papiol S, Rosa A, Gutierrez B, Martín B, Salgado P, Catalan R, Arias B, Fanßanas L. 2004. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet 41:219-223.
30. Prolo P, Licinio J. 1999. Cytokines in affective disorders and schizophrenia: New clinical and genetic findings. Mol Psychiatry 4:109-111.
31. Rudolf S, Peters M, Rothermundt M, Arolt V, Kirchner H. 2002. The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro. Neuropsychobiology 46:180-185.
32. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. 1987. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 238:522-524.
33. Sirota P, Meiman M, Herschko R, Bessler H. 2005. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 134:151-159.
34. Staddon S, Arranz MJ, Mancama D, Mata I, Kerwin RW. 2002. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 162:18-23.
35. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW. 1993. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 9:403-404.
36. Toyooka K, Watanabe Y, Iritani S. 2003. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci Res 46:299-307.
37. Vamvakopoulos J, Green C, Metcalfe S. 2002. Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 32:2988-2996.
38. Witkin SS, Gerber S, Ledger WJ. 2002. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34:204-209.
39. Zanardini R, Bocchio-Chiavetto L, Scassellati C, Bonvicini C, Tura GB, Rossi G, Perez J, Gennarelli M. 2003. Association between IL-1 beta -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. J Psychiatr Res 37:457-462.
40. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. 2004. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J Clin Psychiatry 65:940-947.